Figure 1 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging
Huang Y-J., Rieder J., Tan KV., Tenditnaya A., Vojnovic B., Gorpas D., Quante M., Vallis KA.
<p>c-MET is upregulated in Barrett’s esophagus and esophageal adenocarcinoma compared with normal epithelium: <b>A</b> and <b>B</b>, Upregulation of <i>MET</i> mRNA in Barrett’s esophagus and esophageal adenocarcinoma in two GEO databases in comparison with NSE. <b>C,</b> Representative immunostaining of normal epithelium, inflammation, hyperplasia, and esophageal adenocarcinoma. <b>D,</b> Analysis of human TMAs confirmed upregulation of c-MET protein in esophageal adenocarcinoma compared with NSE, inflammation, and hyperplasia (all <i>P</i> < 0.0001). <b>E</b> and <b>F,</b> Immunostaining of endoscopic human biopsy samples of NSE (<i>n</i> = 6) and Barrett’s esophagus (<i>n</i> = 5) showed an approximately 2-fold greater average H-score and percentage of c-MET positivity in Barrett’s esophagus compared with NSE. **, <i>P</i> < 0.01; ****, <i>P</i> < 0.0001.</p>